検索結果

千寿製薬株式会社

c suspension 0.3%, a novel treatment of Dry Eye Disease through Transient Receptor Potential cation channel subfamily V member 1 Inhibition（PDF） 2025年09月04日 Senju has developed and obtained approval f...

Meetings of the Minds | Research & Development | SENJU Pharmaceutica

erica Antagonistic activity and selectivity of SJP-0132 against transient receptor potential cation channel subfamily V member 1 Tomoka Uemura1, Hideharu Uchida2, Chika Higashi2, Ken-ichi Amano2, Atsu...

Meetings of the Minds | Research & Development | SENJU Pharmaceutica

erica Antagonistic activity and selectivity of SJP-0132 against transient receptor potential cation channel subfamily V member 1 Tomoka Uemura1, Hideharu Uchida2, Chika Higashi2, Ken-ichi Amano2, Atsu...

お知らせ | 千寿製薬株式会社

c suspension 0.3%, a novel treatment of Dry Eye Disease through Transient Receptor Potential cation channel subfamily V member 1 Inhibition（PDF） September 4, 2025 Senju has developed and obtained appr...

ともご指導、ご厚情を賜ります ようお願い申しあげます。 謹白 製品名 アバレプト懸濁性点眼液0.3％ 一般名 モツギバトレプ ※Transient receptor potential cation channel subfamily V member 1 効能又は効果 ドライアイ ドライアイ治療剤 （TRPV1※ 拮抗薬）